Lyra Therapeutics (LYRA) Current Assets (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Current Assets of $16.3 million in Q4 2025, down 29.31% on a QoQ basis from $23.0 million in Q3 2025, and down 62.18% YoY from $43.0 million in Q4 2024.
Lyra Therapeutics (LYRA) Current Assets (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Current Assets for 7 consecutive years, with $16.3 million the latest figure, recorded in Q4 2025.
- Current Assets for Q4 2025 came in at $16.3 million, down 62.18% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.3 million (down 62.18% YoY), and the FY2025 annual result was $16.3 million, down 62.18% from the prior year.
- Current Assets for Q4 2025 stood at $16.3 million, down from $23.0 million in the prior quarter.
- The five-year high for Current Assets was $122.4 million in Q2 2022, with the low at $16.3 million in Q4 2025.
- A 5-year average of $69.8 million and a median of $68.4 million in 2021 frame the typical range for Current Assets.
- Across the five-year window, Current Assets soared 110.42% in 2022 and slumped 62.18% in 2025, its largest moves.
- Lyra Therapeutics' Current Assets stood at $47.9 million in 2021, then soared by 110.42% to $100.8 million in 2022, then climbed by 3.96% to $104.8 million in 2023, then tumbled by 58.95% to $43.0 million in 2024, then tumbled by 62.18% to $16.3 million in 2025.
- The last three Current Assets figures came in at $16.3 million (Q4 2025), $23.0 million (Q3 2025), and $31.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 16.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.27 Mn |
| Sep 30, 2025 | 23.02 Mn |
| Jun 30, 2025 | 31.06 Mn |
| Mar 31, 2025 | 33.91 Mn |
| Dec 31, 2024 | 43.03 Mn |
| Sep 30, 2024 | 54.44 Mn |
| Jun 30, 2024 | 69.44 Mn |
| Mar 31, 2024 | 89.44 Mn |
| Dec 31, 2023 | 104.82 Mn |
| Sep 30, 2023 | 104.92 Mn |
| Jun 30, 2023 | 118.25 Mn |
| Mar 31, 2023 | 84.80 Mn |
| Dec 31, 2022 | 100.83 Mn |
| Sep 30, 2022 | 112.23 Mn |
| Jun 30, 2022 | 122.38 Mn |
| Mar 31, 2022 | 40.56 Mn |
| Dec 31, 2021 | 47.92 Mn |
| Sep 30, 2021 | 60.89 Mn |
| Jun 30, 2021 | 70.07 Mn |
| Mar 31, 2021 | 67.35 Mn |